GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review additional materials submitted by the company, suggesting the company may ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

GSK's Blenrep Drug Recommended for Approval by European Medicines Agency Provided by Dow Jones May 23, 2025, 12:02:00 PM. By Nina Kienle .

Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from the market in 2022 after the drug failed in a study meant to confirm its benefit ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...